review of efficacy and safety of duloxetine 40 to 60？mg once daily in patients with diabetic peripheral neuropathic pain回顾40到60度洛西汀的疗效和安全性毫克每天一次患者糖尿病周围神经性疼痛.pdfVIP

Hindawi Publishing Corporation Pain Research and Treatment Volume 2012, Article ID 898347, 12 pages doi:10.1155/2012/898347 Review Article Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain Vladimir Skljarevski,1 Elijah P. Frakes,1 Doron Sagman,2 Sarah Lipsius,3 3 ´ ˜ 4 Alexandra N. Heinloth, and Hector J. Duenas Tentori 1 Department of Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA 2 Department of Neuroscience, Eli Lilly Canada, Toronto, Canada ON M1N 2E8 3 Department of Strategic Resourcing, PharmaNet/i3, Ann Arbor, MI 48108, USA 4 Department of Neuroscience, Eli Lilly de Mexico, 03900 Mexico, Mexico ´ ´ Correspondence should be addressed to Elijah P. Frakes, efrakes@ Received 10 January 2012; Revised 16 April 2012; Accepted 7 May 2012 Academic Editor: Bjorn Meyerson Copyright © 2012 Vladimir Skljarevski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We summarize efficacy and safety findings from 4 double-blind, placebo-controlled, 12-week studies and 1 open-label, uncontrolled, 34-week maintenance-of-effect (MOE) study that examine duloxetine 40 and 60 mg once daily (QD) in patients with diabetic peripheral neuropathic pain (DPNP). In all placebo-controlled studies, duloxetine showed significantly (P ≤ .01) greater reduction in pain severity (weekly mean of 24-hour average pain severity ratings, primary outcome measure)